(Louisville, Ky) – Nearly ten years ago John Trent Ph.D. of the Molecular Modeling Facility at UofL used the combined power of thousands of computers in classrooms across the state of Kentucky to discover potential compounds that stop cancer from growing. The University recently announced that their research team is now at a point in the development process to secure a commercial partner to take the technology to the next step.
READ STORY FROM UofL BELOW
John Trent and this team executed several runs on the DataseamGrid in the spring of 2007. The Grid helped the
research team narrow their search of over 12 million potential compounds to about 100 of interest, which they took to the laboratory for further analysis and development. Additional validation was done on the Grid against larger database of compounds in late 2010. Like most drugs it would take another decade to narrow the candidates, modify compounds, test and retest before proving they had a potentially viable treatment.
STOPS GROWTH OF ONE-THIRD OF HUMAN TUMORS
At the time the DataseamGrid consisted of about 7,000 machines running in 39 school districts. There where still a number of the early “white” iMacs and even some of the egg-shaped eMacs doing their job both in the classroom and
powering research. With more computers and faster processors the current Grid produces ten times the processing speed and
allows researchers to search with greater accuracy and look at many more possibilities. The current library is 34 million.
This added power helps UofL cancer researchers not only continue to make groundbreaking discoveries, but also makes it possible for them to attract millions of dollars in federal research grants, talented faculty and researchers, and potential business to the Commonwealth.
(Published July 22, 2020 from University of Louisville)
UOFL TECHNOLOGY THAT MAY INHIBIT PATHWAY FOR CANCER GETS COMMERCIAL PARTNER
By Betty Coffman
LOUISVILLE, Ky. — A University of Louisville-born invention that may help treat cancer now has a commercial partner.
Qualigen Therapeutics Inc., a California biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, has signed a license agreement for the technology and plans to fund continued development with UofL to ready it for market.
The technology works by targeting the RAS protein, which sends signals that regulate when and where the body produces and grows new cells. When mutated, the protein turns into a “stuck accelerator pedal,” according to UofL researcher Geoffrey Clark, Ph.D., who co-invented the technology with colleagues John Trent, Ph.D., and Joe Burlison, Ph.D.
“Normally, it gets pressed when you need to grow and then the foot comes off and the cell slows down,” said Clark, professor of pharmacology and toxicology at UofL. “When it becomes mutated, the accelerator’s jammed on, with cells continuing to grow and ultimately becoming a cancerous tumor.”
The drug targets only the active RAS protein and, so far, has little toxic effect on healthy cells. Many current non-targeted treatments, such as chemotherapy, can hurt both healthy and cancerous cells, leading to painful side effects. By some estimates, targeting this mutation could stop the growth of at least a third of human tumors.
“The patient impact could be extremely broad because RAS is involved in a lot of different cancers,” Trent said. “It’s one of the holy grails that there has been limited success in targeting.”
Trent leads the Molecular Modeling Facility (MMF) at UofL Health – James Graham Brown Cancer Center and the UofL partnership with Dataseam, a non-profit with a network of school computers across the state. When the computers aren’t being used by students, they’re connected to act as a distributed supercomputer, allowing researchers to process and analyze huge amounts of data.
Trent used that capability to run through millions of cancer-fighting drug possibilities in a matter of days. The result was a drug that could inhibit the deregulated RAS protein. Development of the technology was supported by the UofL NIH REACH ExCITE program.
Qualigen holds an exclusive license to the technology through the UofL Commercialization EPI-Center, which works with startups and industry to commercialize university-owned technologies. This license agreement builds on a sponsored research agreement with Qualigen for the development of several small-molecule RAS Inhibitor drug candidates. Qualigen also has licensed and is developing other UofL technologies for fighting COVID-19 and cancer.
“Partnering on this new cancer-fighting technology is another example of the relationship we’ve developed with the University of Louisville,” said Michael Poirier, CEO of Qualigen. “We look forward to working with UofL and to advancing this important clinical program with the goal of developing an effective treatment for this unmet need.”
Dataseam CEO Brian Gupton and UofL Brown Cancer Center Deputy Director, Dr. John Trent, discuss Dataseam’s value providing computers to school classrooms across Kentucky while delivering computer power to cancer researchers at UofL. The story is the first feature segment on UofL Today with Mark Hebert radio show.
Listen to the story: UofL Today with Mark Hebert: Dataseam/Cancer Research.
Originally aired on FM 93.9, March 12, 2018.
In the first 70 days of the calendar year, the DataseamGrid completed over 1,000 years of critical cancer research. Since January 1, 2017 researchers at the James Graham Brown Cancer Center have used this massive Kentucky cloud-based computing system to investigate tumor suppressor pathways, target specific genes and identify existing drugs that may be used to fight different cancers.
This unique computing system provides 40,000 Gigahertz of processing power from desktop computers sitting in 38 school systems across the state. It extracts the maximum amount of computing power from every system around the clock, not only during evenings and weekends, but also between classes and other low use periods.
As one of the largest distributed computing systems in the world, it supplies twice the raw processing power of dedicated super computing at the University of Kentucky and University of Louisville combined. If you purchased that much power from traditional cloud-based services, the state would have paid nearly $500,000 since early January.
Teams of Kentucky-based researchers have been looking at over 130 targets against their database of 25 million potential compounds to identify potential drugs. They have also extended their search efforts to scan national databases of thousands of drugs including FDA approved drugs, to determine if some of those drugs might be useful against other types of cancers and different treatment programs.
The potential to repurpose existing medicines or substances may help get the benefits to people more quickly. It is an area of focus for the NIH (National Institutes of Health) and University of Louisville cancer research teams are concentrating efforts in this area.
Supported and maintained across 38 school districts from Pikeville and Martin County in the east to Union and Crittenden Counties in the west, these 12,000 plus school computers take on these research requests that might consist of 50,000 individual tasks, with each task taking many hours to complete. If local equipment, network or power conditions put a school or school system offline for any time, the system dynamically redirects tasks to other available computers so the important research marches on 24-hours a day, seven days a week.
Dataseam developed and manages the DataseamGrid in collaboration with 38 Kentucky school districts. Dataseam also works with local school districts, universities and academies to promote STEM educated workforce, particularly in bio-medical research and aerospace industries. Over 7,000 teachers and 90 technicians participate in training and industry-based certification programs as part of this effort.
 Computing power based on number of intel cores as documented at https://www.rc.uky.edu/high-performance-computing/hpc-hardware/ and http://louisville.edu/it/departments/research/cyberinfrastructure
 Calculated using http://calculator.s3.amazonaws.com